Article
Immunology
Ran Salomon, Rony Dahan
Summary: The clinical use of anti-CD40 agonist monoclonal antibodies faces challenges due to dose-limiting toxicity. Novel approaches are being explored to overcome the systemic toxicity associated with CD40 agonism.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medical Laboratory Technology
Jian-Hang Xue, Yong-Jing Wang, Wei Li, Qiu-Ling Li, Qiu-Yan Xu, Jian-Jun Niu, Li-Li Liu
Summary: There is a strong correlation between neutralizing antibodies and anti-receptor-binding domain (RBD) IgG antibodies, suggesting that anti-RBD IgG antibody levels can accurately assess immunity following SARS-CoV-2 infection or vaccination.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Review
Immunology
Kristina Zlatina, Sebastian P. Galuska
Summary: This review discusses the impact of glycosylation on the function of antibodies, specifically Ig, and how changes in glycosylation affect their functionality. It also explores the functionality of IgG glycosylation in different physiological states, such as aging, lactation, and pathophysiological processes. Additionally, it points out the current knowledge about Ig glycosylation in farm animals and the potential contributions of new advancements in vaccination to animal welfare.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Bruce D. Wines, Halina M. Trist, Sandra Esparon, Rachael E. Impey, Graham A. Mackay, Robert K. Andrews, Tatiana P. Soares da Costa, Geoffrey A. Pietersz, Ross Baker, P. Mark Hogarth
Summary: The activation of Fc gamma RIIa by monoclonal antibodies requires interaction with both the Fab and Fc regions simultaneously on the same receptor molecules.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Yusuke Mimura, Yuka Mimura-Kimura, Radka Saldova, Pauline M. Rudd, Roy Jefferis
Summary: Intravenous immunoglobulin (IVIG) modulates immune responses through Fc gamma receptor IIIa blockade and nonfucosylated IgG glycoforms show higher affinity and inhibitory potency in antibody-dependent cellular cytotoxicity (ADCC). This study provides insights into improved therapeutic strategies for autoimmune/inflammatory diseases using glycoengineered IVIG and recombinant Fc.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Andrew R. Crowley, Matthew R. Mehlenbacher, Mohammad M. Sajadi, Anthony L. DeVico, George K. Lewis, Margaret E. Ackerman
Summary: Antibody-mediated effector functions can unfold according to an associative model of IgG-Fcγ receptor (FcγR) interactions or a competing model of antibody allostery. Evidence supports the antibody allostery model, but it remains controversial.
Article
Cell Biology
Jacqueline M. Brady, Meredith Phelps, Scott W. MacDonald, Evan C. Lam, Adam Nitido, Dylan Parsons, Christine L. Boutros, Cailin E. Deal, Wilfredo F. Garcia-Beltran, Serah Tanno, Harini Natarajan, Margaret E. Ackerman, Vladimir D. Vrbanac, Alejandro B. Balazs
Summary: This study investigates the efficacy and relative contribution of HIV antibodies using a humanized mouse model. The findings suggest that antibodies lacking Fc-mediated functionality have reduced protection against HIV transmission, while highly functional antibodies can provide significant protection against infection.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Simone I. I. Richardson, Frances Ayres, Nelia P. P. Manamela, Brent Oosthuysen, Zanele Makhado, Bronwen E. E. Lambson, Lynn Morris, Penny L. L. Moore
Summary: The study revealed that IgG3 bNAbs demonstrate stronger protective ability and phagocytosis against HIV infection, especially against certain specific HIV strains, indicating that altering the constant region of antibodies may enhance their neutralizing and Fc effector activity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Michaela Seeling, Matthias Poehnl, Sibel Kara, Nathalie Horstmann, Carolina Riemer, Miriam Woehner, Chunguang Liang, Christin Brueckner, Patrick Eiring, Anja Werner, Markus Biburger, Leon Altmann, Martin Schneider, Lukas Amon, Christian H. K. Lehmann, Sooyeon Lee, Meik Kunz, Diana Dudziak, Georg Schett, Tobias Baeuerle, Anja Lux, Jan Tuckermann, Timo Voegtle, Bernhardt Nieswandt, Markus Sauer, Rainer A. Boeckmann, Falk Nimmerjahn
Summary: Immunoglobulin G (IgG) antibodies are major drivers of inflammation, but in pooled serum IgG (IVIg), they have immunomodulatory and anti-inflammatory activity. The mechanism behind this activity is unclear. The study found that IVIg sialylation inhibited joint inflammation in rheumatoid arthritis models, and the inhibition of osteoclastogenesis was independent of sialic acid. Instead, IVIg-dependent inhibition of osteoclastogenesis required the presence of receptors Dectin-1 or FcgRIIb. This research reveals a novel role of Dectin-1 as a co-inhibitory checkpoint for IgG-dependent inhibition of osteoclastogenesis.
Article
Multidisciplinary Sciences
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, Bo Meng, Rawlings P. Datir, Alexandra C. Walls, Steven A. Kemp, Jessica Bassi, Dora Pinto, Chiara Silacci-Fregni, Siro Bianchi, M. Alejandra Tortorici, John Bowen, Katja Culap, Stefano Jaconi, Elisabetta Cameroni, Gyorgy Snell, Matteo S. Pizzuto, Alessandra Franzetti Pellanda, Christian Garzoni, Agostino Riva, Anne Elmer, Nathalie Kingston, Barbara Graves, Laura E. Mccoy, Kenneth G. C. Smith, John R. Bradley, Nigel Temperton, Lourdes Ceron-Gutierrez, Gabriela Barcenas-Morales, William Harvey, Herbert W. Virgin, Antonio Lanzavecchia, Luca Piccoli, Rainer Doffinger, Mark Wills, David Veesler, Davide Corti, Ravindra K. Gupta
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Review
Biochemistry & Molecular Biology
Maxime Fieux, Sandra Le Quellec, Sophie Battier, Andre Coste, Bruno Louis, Caroline Giroudon, Mikail Nourredine, Emilie Bequignon
Summary: FcRn has been shown to efficiently transport biologics across the nasal epithelial barrier in multiple studies reviewed. Limited studies have evaluated the potential toxicity of intranasal delivery of biologics, but they all indicate its safety. Further research is needed to fully understand the pharmacokinetic and pharmacodynamic properties of biologics after intranasal delivery.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Ruixiao Du, Chaoqiang An, Xin Yao, Yiping Wang, Ge Wang, Fan Gao, Lianlian Bian, Yalin Hu, Siyuan Liu, Qiaohui Zhao, Qunying Mao, Zhenglun Liang
Summary: In this study, an anti-CA16 monoclonal antibody (DMA2017) was generated from an epidemic strain of CA16. Although DMA2017 could not neutralize the original and circulating CA16 strains in vitro, it was found to protect suckling mice from a lethal challenge with CA16 in vivo through Fc-dependent effector functions. The linear epitope of DMA2017 was mapped to a conserved patch of residues 143-148 (NSHPPY) on the VP2 EF-loop of CA16. This research highlights the potential preventive and therapeutic effect of non-neutralizing antibodies and provides insights for the design and evaluation of CA16 vaccines.
EMERGING MICROBES & INFECTIONS
(2023)
Review
Immunology
Stephen R. Walsh, Michael S. Seaman
Summary: The current clinical studies are actively exploring the use of bnAbs as passive immunization strategies to prevent HIV-1 infection. Recent trials have shown that bnAbs can provide protection against HIV-1 infection in humans, but there are still significant barriers to overcome.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Ian Wilkinson, Geoff Hale
Summary: By assembling a dataset of amino acid sequences of antibody-related therapeutics, this study provides insights into trends in antibody engineering and a guide to frequently tested designs.
Article
Clinical Neurology
Vera Bril, Michael Benatar, Henning Andersen, John Vissing, Melissa Brock, Bernhard Greve, Peter Kiessling, Franz Woltering, Laura Griffin, Peter van den Bergh
Summary: This study investigated the clinical efficacy and safety of subcutaneous rozanolixizumab in patients with gMG. While the primary endpoint of change in QMG score was not statistically significant, overall data suggest that rozanolixizumab may provide clinical benefit in patients with gMG and was generally well tolerated. Phase 3 evaluation is ongoing.
Article
Hematology
Katja Klausz, Michael Cieker, Christian Kellner, Thies Roesner, Anna Otte, Steffen Krohn, Anja Lux, Falk Nimmerjahn, Thomas Valerius, Martin Gramatzki, Matthias Peipp
Summary: The novel therapeutic antibody TP15, targeting ICAM-1, showed significant anti-tumor activity by inducing antibody-dependent cell-mediated cytotoxicity. It prevented myeloma cell engraftment and prolonged survival in a mouse model, demonstrating potential for myeloma immunotherapy.
Article
Immunology
Sina Bondza, Anita Marosan, Sibel Kara, Josephine Loesing, Matthias Peipp, Falk Nimmerjahn, Jos Buijs, Anja Lux
Summary: Monoclonal antibodies targeting CD20 on B cells are commonly used in therapy, with differences in their mechanisms of inducing B cell depletion, particularly in terms of complement activation.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Immunology
Falk Nimmerjahn, Jeffrey V. Ravetch
Summary: The study by Grey and Kunkel in 1964 laid the groundwork for our current understanding of the differential IgG subclass activity in protective and self-reactive immune responses.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Lukas Hatscher, Christian H. K. Lehmann, Ariawan Purbojo, Constantin Onderka, Chunguang Liang, Arndt Hartmann, Robert Cesnjevar, Heiko Bruns, Olaf Gross, Falk Nimmerjahn, Ivana Ivanovic-Burmazovic, Meik Kunz, Lukas Heger, Diana Dudziak
Summary: The conventional type 2 DC (cDC2) subset has been found to be transcriptionally and functionally poised for inflammasome formation and response without pyroptosis when stimulated with relatively weak inflammasome activators, leading to the induction of prominent T helper type 1 (T(H)1) and T(H)17 responses. These findings suggest that the human cDC2 subpopulation could be a prime target for the treatment of inflammasome-dependent inflammatory diseases and provide insights for new approaches in adjuvant and vaccine development.
Article
Oncology
A. Stoll, H. Bruns, M. Fuchs, S. Voelkl, F. Nimmerjahn, M. Kunz, M. Peipp, A. Mackensen, D. Mougiakakos
Summary: CD137 plays a crucial role in monocytes, and its agonists may have therapeutic implications in combination with tumor-targeting antibodies, potentially showing synergistic effects.
Article
Multidisciplinary Sciences
Anja Werner, Simon Schafer, Olga Zaytseva, Heike Albert, Anja Lux, Jasminka Kristic, Marija Pezer, Gordan Lauc, Thomas Winkler, Falk Nimmerjahn
Summary: Systemic lupus erythematosus (SLE) is characterized by loss of self-tolerance, systemic inflammation, and multi-organ damage. Early diagnosis and treatment are crucial for achieving long-lasting therapeutic responses and limiting irreversible organ damage. Loss of humoral tolerance before clinical autoimmune disease onset provides a potential early intervention point.
Review
Clinical Neurology
Tobias Ruck, Falk Nimmerjahn, Heinz Wiendl, Jan D. Luenemann
Summary: Ruck et al. provide an overview of advancements in next-generation antibody-based therapies for brain diseases, focusing on Fc engineering and improving bioavailability in the CNS parenchyma. They discuss the potential benefits and limitations of these therapies in neurology. Antibody-based treatments have become standard in neuroinflammatory diseases, and efforts are being made to expand their use to a wider range of neurological disorders. The specificity and effectiveness of these treatments are determined by engineering the antigen-binding fragment (Fab) and the crystallizable fragment (Fc) of the antibodies. The development of technologies to enhance the bioavailability of these treatments within the brain shows promise for improving options for patients with limited therapeutic choices.
Article
Immunology
Kerstin Renner, Sophia Neumayer, Yvonne Talke, Simone Buchtler, Kathrin Schmidbauer, Falk Nimmerjahn, Anja Lux, Frederike Winter, Jan-Nicklas Salewski, Matthias Mack
Summary: B-cell modulation through targeting CD79b can achieve therapeutic effects in autoimmune diseases like MS, offering an alternative approach to complete B-cell depletion with anti-CD20 antibodies.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Editorial Material
Immunology
Anja Werner, Falk Nimmerjahn
Summary: Two recent studies in Science Immunology demonstrate that the hinge region of immunoglobulin G (IgG) is a major regulator of IgG2 and IgG3 activity. Engineering of the IgG hinge may be useful for optimizing the activity of IgG subclasses.
SCIENCE IMMUNOLOGY
(2022)
Correction
Immunology
Falk Nimmerjahn, Gestur Vidarsson, Mark S. S. Cragg
Review
Immunology
Falk Nimmerjahn, Gestur Vidarsson, Mark S. Cragg
Summary: Humoral immune responses generate polyclonal antibodies with varied isotypes, epitope specificity, and affinity. Posttranslational modifications in antibody variable and constant domains can modify antigen specificity and antibody Fc-dependent functions. Understanding the impact of these modifications on antibody function is still limited, but it has implications for therapeutic antibody development. This Review provides insights into how IgG subclass and posttranslational modifications influence antibody activity and discusses their implications in designing therapeutic antibodies for different clinical indications.
Correction
Immunology
Falk Nimmerjahn, Gestur Vidarsson, Mark S. Cragg
Review
Immunology
Elvira Mass, Falk Nimmerjahn, Katrin Kierdorf, Andreas Schlitzer
Summary: Macrophages play important roles in host immunity, waste clearance, metabolism regulation, and neuronal functions. They form a 3D network in tissues and phagocytose dying cells, immune complexes, bacteria, and waste products, while also producing growth factors and signaling molecules. Macrophages are involved in physiological processes such as blood vessel formation, adipogenesis, metabolism, and neuronal function. Different tissue-specific macrophage populations have distinct developmental trajectories, transcriptional programs, and life cycles.
NATURE REVIEWS IMMUNOLOGY
(2023)
Letter
Biochemistry & Molecular Biology
Anja Werner, Falk Nimmerjahn
Summary: The presence or absence of terminal sialic acid residues in the sugar moiety attached to the Fc-domain of IgG molecules plays a role in modulating IgG activity and is associated with autoimmune or infection-related inflammation. Recent findings by Oswald and colleagues propose that IgG sialylation may occur post IgG secretion, which has implications for therapeutic antibodies. However, we argue that previous research suggests that IgG sialylation actually occurs within B cells and question the suitability of the experimental system employed by the authors to address this question.